Translate Bio News Releases http://investors.translate.bio/ Translate Bio News Releases en Translate Bio to Present at the Jefferies 2019 Healthcare Conference http://investors.translate.bio/news-releases/news-release-details/translate-bio-present-jefferies-2019-healthcare-conference LEXINGTON, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Tue, 28 May 2019 07:30:00 -0400 Translate Bio News Releases 6956 Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update http://investors.translate.bio/news-releases/news-release-details/translate-bio-announces-first-quarter-2019-financial-results-and -- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; data expected 3Q19 -- LEXINGTON, Mass. , May 09, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of Thu, 09 May 2019 16:23:00 -0400 Translate Bio News Releases 6936 Translate Bio Announces $47.5 Million Private Placement http://investors.translate.bio/news-releases/news-release-details/translate-bio-announces-475-million-private-placement LEXINGTON, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced today that it has Wed, 01 May 2019 07:30:00 -0400 Translate Bio News Releases 6916 Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting http://investors.translate.bio/news-releases/news-release-details/translate-bio-announces-oral-presentation-mrna-therapeutics -- Preclinical results demonstrate successful delivery of lipid-nanoparticle encapsulated mRNA in relevant metabolic disease models -- LEXINGTON, Mass. , April 29, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a Mon, 29 Apr 2019 08:45:00 -0400 Translate Bio News Releases 6906 Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors http://investors.translate.bio/news-releases/news-release-details/translate-bio-appoints-robert-plenge-md-phd-its-board-directors -- Appointment adds deep translational medicine expertise to support the Company’s mission of developing mRNA therapeutics for rare genetic diseases -- LEXINGTON, Mass. , April 11, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics Thu, 11 Apr 2019 07:30:00 -0400 Translate Bio News Releases 6861 Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting http://investors.translate.bio/news-releases/news-release-details/translate-bio-presents-preclinical-data-supporting-mrt5201 -- MRT5201 was efficiently delivered to the liver of a mouse model of OTC deficiency -- -- Preclinical data demonstrated a single IV dose of MRT5201 was sufficient to protect against hyperammonemia for up to 4 weeks -- LEXINGTON, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. Mon, 08 Apr 2019 16:05:00 -0400 Translate Bio News Releases 6856 Translate Bio Appoints Richard Wooster as Chief Scientific Officer http://investors.translate.bio/news-releases/news-release-details/translate-bio-appoints-richard-wooster-chief-scientific-officer -- Appointment strengthens scientific leadership team and highlights the Company’s commitment to innovative mRNA research and development -- LEXINGTON, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company Mon, 08 Apr 2019 07:30:00 -0400 Translate Bio News Releases 6846 Translate Bio Appoints Pasquale (Pat) Sacco as Senior Vice President of Technical Operations http://investors.translate.bio/news-releases/news-release-details/translate-bio-appoints-pasquale-pat-sacco-senior-vice-president -- New role expands Company’s manufacturing expertise to support pipeline of mRNA therapeutics in development for rare, genetic diseases -- LEXINGTON, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new Mon, 01 Apr 2019 07:30:00 -0400 Translate Bio News Releases 6841 Translate Bio Granted U.S. Patent Relating to Messenger RNA (mRNA) Delivery http://investors.translate.bio/news-releases/news-release-details/translate-bio-granted-us-patent-relating-messenger-rna-mrna Patent provides coverage for lipid-nanoparticle delivery of encapsulated mRNA where the encoded protein or peptide is secreted LEXINGTON, Mass. , March 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of Tue, 26 Mar 2019 07:30:00 -0400 Translate Bio News Releases 6831 Translate Bio to Participate in Upcoming Investor Conferences http://investors.translate.bio/news-releases/news-release-details/translate-bio-participate-upcoming-investor-conferences-0 LEXINGTON, Mass. , March 25, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Company Mon, 25 Mar 2019 07:30:00 -0400 Translate Bio News Releases 6826